umbralisib   Click here for help

GtoPdb Ligand ID: 8916

Synonyms: example A1 [US2014011819] | RP-5264 | RP5264 | TGR-1202 | TGR1202 | Ukoniq®
Approved drug Immunopharmacology Ligand
umbralisib is an approved drug (FDA (2021))
Compound class: Synthetic organic
Comment: Umbralisib (TGR-1202; RP5264,) is an orally available, selective inhibitor of the δ isoform of phosphoinositide 3-kinase (PI3K) [1,3,5], that was developed by TG Therapeutics for the treatment of several B cell malignancies. It also inhibits casein kinase-1ε [2]. For clinical application umbralisib is formulated as the tosylate salt.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 109.06
Molecular weight 571.18
XLogP 8.24
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(Oc1ccc(cc1F)c1nn(c2c1c(N)ncn2)C(c1oc2ccc(cc2c(=O)c1c1cccc(c1)F)F)C)C
Isomeric SMILES CC(Oc1ccc(cc1F)c1nn(c2c1c(N)ncn2)[C@H](c1oc2ccc(cc2c(=O)c1c1cccc(c1)F)F)C)C
InChI InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
InChI Key IUVCFHHAEHNCFT-INIZCTEOSA-N
References
1. Barrientos JC. (2018)
Can umbralisib bring PI3Kδ out of the shadows?.
Lancet Oncol, 19 (4): 432-434. [PMID:29475725]
2. Burris 3rd HA, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP et al.. (2018)
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Lancet Oncol, 19 (4): 486-496. [PMID:29475723]
3. Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX et al.. (2017)
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.
Blood, 129 (1): 88-99. [PMID:27784673]
4. TG Therapeutics. 
TG Therapeutics Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Umbralisib for the Treatment of Marginal Zone Lymphoma.
Accessed on 29/01/2019. Modified on 29/01/2019. TG Therapeutics, http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-receives-breakthrough-therapy-designation-us
5. Vakkalanka SKVS, Muthuppalaniappan M, Nagarathnam D. (2014)
Novel selective pi3k delta inhibitors.
Patent number: US20140011819 A1. Assignee: Rhizen Pharmaceuticals Sa.. Priority date: 04/07/2012. Publication date: 09/01/2014.